Project ID Card - uniroma1.it · October 1st 2012 . Duration: 36 months. Contact: Prof. F.Michelotti (Project Coordinator ) [email protected]. 2. Partnership. Università

1

Project ID CardFunded under: EU 7th Seventh Framework Programme

Topic: ICT 2011.3.5.a Core Photonic Technologies

Subtopic (2) Biophotonics for early, fast and reliable medical diagnosis

Reference: 318035

Total cost: 4.73 M€

EU contribution: 3.60 M€

Start Date: October 1st 2012

Duration: 36 months

Contact: Prof. F.Michelotti (Project Coordinator )[email protected]

2

PartnershipUniversità degli Studi di Roma “La Sapienza”

Department of Basic and Applied Sciences for EngineeringPolitecnico di Torino

Department of Applied Sciences and TechnologyFraunhofer Gesellschaft zur Förderung der Angewandten Forschung

Unit a - IOF - Institut für Angewandte Optik und FeinmechanikUnit b - IWS - Institut für Werkstoff-und Strahltechnik

Imperial College LondonDepartment of Materials

Università degli Studi di TorinoDepartment of Oncology

Labor, SrlBiotray, SASHoriba Jobin Yvon, SASKDS Radeberg, GmbH

3

European Dimension

4

Objectives

5

Developing a compact and multifunctional point-of-care platformperforming real-time cancer biomarker detection in a tandem label-free and fluorescence configuration.

The bio-sensing platform will consist of:

- Disposable and low cost dielectric 1D photonic crystal biochips

- Reading device

Validating at pre-clinical stage the platform by the detection at avery low concentration of Angiopoietins -1 and -2 which have beenidentified as tumor inducers.

Concept

6

Properly designed 1DPC can sustain Bloch electromagnetic SurfaceWaves (BSW) at the interface, whose peculiar properties can beexploited for overcoming the limitations to sensitivity, selectivity,and resolution of present point-of-care cancer diagnostic tools andthus lead to a new class of advanced industrial products.

Concept

7

• S=20°/RIU• W=0.02°• D=1

FOM=60 RIU-1

@ 804nmFOM=1000 RIU-1

@ 804nmWDSFOM ×=

• S=100°/RIU• W=1.7°• D=1

Enhancement of the label-free operation performance

W

S

D

SPP BSW

Concept

8

Enhancement of the fluorescence operation performance

Single λenhancement 560

Integral enhancement 100

ObjectivesObjective Target value Value of state of the art

SPR platformsSensitivity of amplitude-based

sensors to refractive index changes 30 RIU-1 150 RIU-1

Resolution for refractive index changes ∆n<5·10-8 RIU ∆n~2·10-7 RIU

Field enhancement factor for improving fluorescence intensity 5000 100

Integration of label-free and enhanced fluorescence detection YES NOT EXISTING

Resolution for detectable cancer biomarkers concentration

10ng/mL(label-free)

<0.1ng/ml (fluo)

10ng/mL for Prostate Specific Antigen biomarkers

64 ng/mL for activatedleukocyte cell adhesion molecule biomarkers

9

Workplan

10

Exploitation potential

11

The BILOBA platform represents a breakthrough in ultra-sensitive photonic systems for non invasive and point of careearly diagnosis of cancer.BILOBA can potentially outperform conventional approachesand set a new standard for early recognition of malignancies.The increased performance of the BSW biochips will have atremendous impact on the medical community, allowing cancerdiagnosis at a very early stage with consequent increase ofquality of life for the patients, increase of lifetime, and decreaseof treatment costs.Horiba Jobin Yvon is leading the exploitation activities as it iswell placed in the market which can directly exploit the BILOBAtechnology.

Contact

12

Francesco Michelotti [email protected]

Emiliano Descrovi [email protected]

Norbert Danz [email protected]

Molly Stevens [email protected]

Federico Bussolino [email protected]

Paolo De Stefanis [email protected]

Raphael Anasthase [email protected]

Chiraz Frydman [email protected]

Thomas Schubert [email protected]